scispace - formally typeset
D

Dennis A. Gastineau

Researcher at Mayo Clinic

Publications -  207
Citations -  10076

Dennis A. Gastineau is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Transplantation & Multiple myeloma. The author has an hindex of 55, co-authored 206 publications receiving 9133 citations. Previous affiliations of Dennis A. Gastineau include University of Rochester & University of Lisbon.

Papers
More filters
Journal ArticleDOI

Single dose streptozotocin-induced diabetes: considerations for study design in islet transplantation models.

TL;DR: The literature is reviewed and data from pancreatic islet transplantation experiments using single high-dose STZ-induced DM in NCr athymic nude mice are provided with hopes of providing clarification for study design, suggesting refinements to the process, and developing a more humane process of chemical diabetes induction.
Journal ArticleDOI

Bleeding, Blood Transfusion, and Increased Mortality After Percutaneous Coronary Intervention: Implications for Contemporary Practice

TL;DR: The basis for a possible causal link between post-PCI bleeding and subsequent mortality is examined and possible mechanisms underpinning such a link are discussed, including a potential adverse role for blood transfusion in this setting.
Journal ArticleDOI

Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma.

TL;DR: A trend was seen towards decreased PBSC yield with increasing duration of lenalidomide therapy as well as increasing age, and there was no effect on quality of PBSC collected based on similar engraftment across all groups.
Journal ArticleDOI

Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma.

TL;DR: ALC is correlated with clinical outcome and requires further study, and Multivariate analysis demonstrated day 15 ALC to be an independent prognostic indicator for OS and PFS rates for both groups of patients.